Tianshui Zhongxing Bio-technology Co Ltd (002772) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Tianshui Zhongxing Bio-technology Co Ltd stock ¥6.42, price ¥7.90, that is 18.8% below the price, quality 58 out of 100. Rating: overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range ¥5.22 – ¥19.19 · fair‑value band ¥4.47 – ¥8.57 · the ¥7.90 price screens above the ¥6.42 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Tianshui Zhongxing Bio-technology Co in your weekly email
Every Wednesday you see whether Tianshui Zhongxing Bio-technology Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Tianshui Zhongxing Bio-technology Co.,Ltd., together with its subsidiaries, engages in the research and development, production and sales of edible mushrooms in China and internationally. It offers enoki and button mushrooms; cordyceps militaris; and cordyceps sinensis.
Show moreShow less
The company also engages in agriculture planting, investment management, and real estate development businesses. Tianshui Zhongxing Bio-technology Co.,Ltd. was founded in 2005 and is headquartered in Tianshui, China.
Stock analysis
Tianshui Zhongxing Bio-technology Co Ltd (002772) currently trades at ¥7.90, while our model-based Fair Value estimate is ¥6.42, 19% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥22.63 per share, and 10 of the 16 models we run sit above the ¥7.90 price.
Bear case: the Dividend Discount group reads lowest at ¥4.07, and 6 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ¥4.47 (bear) to ¥8.57 (bull), the price of ¥7.90 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Consumer Defensive sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Tianshui Zhongxing Bio-technology Co Ltd reported revenue of 2.1B CNY in FY2025 versus 1.6B CNY in FY2021, a compound +7.8%/yr. Reported net income was 335M CNY in FY2025, compounding +57.1%/yr from FY2021.
Key figures
Market cap 3.0B CNY (≈ $446M) Small · P/E ratio 14.9 · P/S ratio 1.33 · EPS (TTM) ¥0.5300 · Dividend yield 3.8% · Net margin 9.6% · Return on equity 6.3% · Return on assets (EBIT) 2.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 40 out of 100 (low confidence).
What moves the price
The share trades about 59% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at 6% fair-value upside, at −19%, 002772 screens richer than that median.
Fair Value models
Bear¥4.47Fair Value ¥6.42Bull¥8.57
Price ¥7.90 · Downside -18.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.1966 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income¥7.70¥8.29¥9.4176
EPV¥5.21¥6.08¥6.8174
ROIC Compounder¥5.21¥6.08¥6.8172
All 16 models by family
Earnings-Based
Graham-Dodd¥6.08¥38.61¥53.9663
Lynch FV¥11.16¥15.95¥20.7361
PEG = 1.0¥11.16¥15.95¥20.7357
EPV¥5.21¥6.08¥6.8174
Dividend Discount
Gordon GGM¥2.35¥4.25¥5.8868
DDM Multi-Stage¥2.35¥3.88¥4.5467
Multiples
P/E Multiple¥14.08¥18.77¥23.4663
P/S Multiple¥6.72¥8.96¥11.2058
P/B Multiple¥7.00¥9.33¥11.6755
EV/EBIT¥7.33¥11.06¥14.7865
EV/EBITDA¥11.35¥16.41¥21.4767
EV/Revenue¥2.04¥4.56¥7.0851
Asset-Based
NCAV (Graham)¥4.23¥5.66¥8.4554
Economic Profit
Residual Income¥7.70¥8.29¥9.4176
ROIC Compounder¥5.21¥6.08¥6.8172
Growth Earnings
Growth-Adj P/E¥15.84¥22.63¥29.4167
The fair value above starts from this blend and is adjusted for a cyclical peak year.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+8.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.2%
Start year 2020 (pandemic). Over 10 years: +15.9% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
≈ +13.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +9.7%
Dividend (yield on the price)3.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 36.2% / 8.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 16%
2025 sits 128% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
⚠ Base effect: the rate starts in the earnings trough around 2020 (starting value 0.19 per share, median 0.39 in 2015 to 2018). It measures the recovery from the trough, not lasting growth.
Compare Tianshui Zhongxing Bio-technology Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Farm Products · 291 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside−18.8% · Below median
Profitability
Return on equity (12 months)6.3% · Above median
Return on assets4.7% · Above median
Net margin (12 months)9.6% · Top 25%
Operating margin (12 months)4.3% · Below median
Growth and dividend
Revenue growth (quarter YoY)−8.5% · Bottom 25%
Dividend yield (12 months)3.8% · Above median
Balance sheet
Debt / equity0.53× · Highest 25%
Valuation Multiplesvs Farm Products median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Tianshui Zhongxing Bio-technology Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/002772
Frequently asked questions
Is Tianshui Zhongxing Bio-technology Co Ltd (002772) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of ¥6.42 versus a price of ¥7.90, about 19% lower (overvalued).
What is the fair value of 002772?
Our model-based fair value for Tianshui Zhongxing Bio-technology Co Ltd is ¥6.42 (as of Nov 8, 2026), built from audited fundamentals. The current price: ¥7.90.
What is the quality score of 002772?
Tianshui Zhongxing Bio-technology Co Ltd has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tianshui Zhongxing Bio-technology Co Ltd (002772)?
Our model-based price target is the fair value of ¥6.42 (as of Nov 8, 2026) from 16 valuation models. Cautious scenario ¥4.47, optimistic scenario ¥8.57. It is a calculation from audited fundamentals, not an analyst target.
What is the Tianshui Zhongxing Bio-technology Co Ltd stock forecast for 2026?
Our models put fair value at ¥6.42, about 19% lower versus a price of ¥7.90 (overvalued). Cautious scenario ¥4.47, optimistic scenario ¥8.57. The calculation is refreshed regularly with new filings.
What is the revenue of Tianshui Zhongxing Bio-technology Co Ltd (002772)?
Tianshui Zhongxing Bio-technology Co Ltd reported trailing-twelve-month revenue of about 2.2B CNY (latest available figure, as of Nov 8, 2026).
Does Tianshui Zhongxing Bio-technology Co Ltd pay a dividend?
Tianshui Zhongxing Bio-technology Co Ltd currently shows a dividend yield of 3.80% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Tianshui Zhongxing Bio-technology Co Ltd (002772) and when is the ex-dividend date?
Tianshui Zhongxing Bio-technology Co Ltd pays a dividend of ¥0.3 per share a year, a dividend yield of 3.8%. The last ex-dividend date was Oct 14, 2026. A dividend has been paid every year since at least 2016. The payout ratio is 56.6% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Tianshui Zhongxing Bio-technology Co Ltd (002772)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tianshui Zhongxing Bio-technology Co Ltd it is ¥6.42 per share (as of Nov 8, 2026), against a price of ¥7.90. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Tianshui Zhongxing Bio-technology Co Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 002772 trades above its calculated fair value: price ¥7.90, fair value ¥6.42, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002772?
No. The price is what the market pays today (¥7.90); the fair value is what the company's own numbers justify (¥6.42). For Tianshui Zhongxing Bio-technology Co Ltd the two are ¥1.48 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tianshui Zhongxing Bio-technology Co Ltd worth?
The market values Tianshui Zhongxing Bio-technology Co Ltd at about 3.0B CNY (market capitalisation, as of Nov 8, 2026). Per share that is ¥7.90; our models calculate a fair value of ¥6.42 per share.
What do the bullish and bearish scenarios say about 002772?
Our models span a range for Tianshui Zhongxing Bio-technology Co Ltd: cautious scenario ¥4.47, base ¥6.42, optimistic ¥8.57 per share (as of Nov 8, 2026, price ¥7.90). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 002772?
Tianshui Zhongxing Bio-technology Co Ltd trades at a price-to-earnings ratio of 14.9 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥6.42 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 22.1. Other multiples: P/B 0.8, P/S 1.3, EV/EBITDA 5.0.
How solid is the balance sheet of Tianshui Zhongxing Bio-technology Co Ltd (002772)?
Balance-sheet figures for Tianshui Zhongxing Bio-technology Co Ltd (as of Nov 8, 2026): return on equity 6.3%, debt of 0.53 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 002772 from its 52-week high?
Tianshui Zhongxing Bio-technology Co Ltd trades at ¥7.90, about 59% below its 52-week high of ¥19.19 and 4% above the low of ¥7.57 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥6.42 is for.
Which stocks are comparable to Tianshui Zhongxing Bio-technology Co Ltd?
From the same area (Consumer Defensive) we also value Muyuan Foods Group, Archer-Daniels-Midland Company, Tyson Foods, Inc, Bunge Global SA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tianshui Zhongxing Bio-technology Co Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price ¥7.90, calculated fair value ¥6.42 (−19%), Quality Score 58/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002772 calculated?
We run Tianshui Zhongxing Bio-technology Co Ltd through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥6.42 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Tianshui Zhongxing Bio-technology Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tianshui Zhongxing Bio-technology Co Ltd (002772)?
The closing price on Nov 6, 2026 was ¥7.90. Our model-based fair value is ¥6.42, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tianshui Zhongxing Bio-technology Co Ltd right now?
Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥4.47 to ¥8.57) leaves room in how you read the outcome.
Key figures of Tianshui Zhongxing Bio-technology Co Ltd
How large is the market capitalisation of Tianshui Zhongxing Bio-technology Co Ltd (002772)?
The market capitalisation of Tianshui Zhongxing Bio-technology Co Ltd is 3.0B CNY (≈ $446M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tianshui Zhongxing Bio-technology Co Ltd (002772)?
The price-to-sales ratio of Tianshui Zhongxing Bio-technology Co Ltd is 1.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tianshui Zhongxing Bio-technology Co Ltd (002772)?
Earnings per share at Tianshui Zhongxing Bio-technology Co Ltd are ¥0.5300 (price ÷ EPS = P/E 14.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Tianshui Zhongxing Bio-technology Co Ltd (002772)?
The dividend yield of Tianshui Zhongxing Bio-technology Co Ltd is 3.8% (payout 56.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Tianshui Zhongxing Bio-technology Co Ltd (002772)?
The net margin of Tianshui Zhongxing Bio-technology Co Ltd is 9.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tianshui Zhongxing Bio-technology Co Ltd (002772)?
The return on equity (ROE) of Tianshui Zhongxing Bio-technology Co Ltd is 6.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tianshui Zhongxing Bio-technology Co Ltd (002772)?
On an EBIT basis the return on assets of Tianshui Zhongxing Bio-technology Co Ltd is 2.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tianshui Zhongxing Bio-technology Co Ltd (002772)?
The operating margin of Tianshui Zhongxing Bio-technology Co Ltd is 4.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tianshui Zhongxing Bio-technology Co Ltd (002772)?
Revenue at Tianshui Zhongxing Bio-technology Co Ltd is growing −8.5% versus a year earlier (3y avg +2.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tianshui Zhongxing Bio-technology Co Ltd (002772)?
Earnings per share at Tianshui Zhongxing Bio-technology Co Ltd are growing +32.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Tianshui Zhongxing Bio-technology Co Ltd (002772) generate?
The free cash flow of Tianshui Zhongxing Bio-technology Co Ltd is −48.0M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Tianshui Zhongxing Bio-technology Co Ltd (002772) carry?
The net debt of Tianshui Zhongxing Bio-technology Co Ltd is 1.4B CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Tianshui Zhongxing Bio-technology Co Ltd in the live analysis
One click puts Tianshui Zhongxing Bio-technology Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026